Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DiagnosDGNOF -4.75%22 Equity-to-Asset is 0.29 as of Mar. 2026. GuruFocus rates DGNOF with a GF Score™ of 22/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 687 Healthcare Providers & Services companies, Diagnos ranks worse than 74.24% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Diagnos's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $0.49 Mil. Diagnos's Total Assets for the quarter that ended in Mar. 2026 was $1.71 Mil.
Therefore, Diagnos's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.29.
The historical rank and industry rank for Diagnos's Equity-to-Asset or its related term are showing as below:
DGNOF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.6 Med: -1.15 Max: 0.75
Current: 0.29
During the past 13 years, the highest Equity to Asset Ratio of Diagnos was 0.75. The lowest was -4.60. And the median was -1.15.
DGNOF's Equity-to-Asset is ranked worse than 74.24% of 687
companies
in the Healthcare Providers & Services industry
Industry Median: 0.49
vs DGNOF: 0.29
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Diagnos Equity-to-Asset Related Terms
Diagnos Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Diagnos's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DGNOF vs VEEV, BTSG, TEM: Equity-to-Asset Comparison
For the Health Information Services subindustry, Diagnos's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnos Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Diagnos's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Diagnos's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnos (DGNOF) has a Equity-to-Asset of 0.29 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Diagnos and its competitors. According to the industry distribution chart, Diagnos ranks #510 out of 687 companies in the Healthcare Providers & Services industry, placing it in the top 74.2%.
Is Diagnos' Equity-to-Asset too high?
Diagnos' current Equity-to-Asset is 0.29. The Healthcare Providers & Services industry median Equity-to-Asset is 0.49. Diagnos' value of 0.29 is 40.8% below this industry median. Based on the distribution chart, Diagnos ranks #510 out of 687 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Diagnos has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnos' Equity-to-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #510 out of 687 companies for Equity-to-Asset. This places Diagnos in the lower half of its industry. The industry median Equity-to-Asset is 0.49. Diagnos' value of 0.29 is 40.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.49, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnos's current Equity-to-Asset of 0.29 is 40.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Diagnos and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnos's current Equity-to-Asset is 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Based on GuruFocus' analysis, Diagnos (DGNOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.34 — trading 577.2% above its estimated fair value. The current Equity-to-Asset is 0.29 and 40.8% below the Healthcare Providers & Services industry median of 0.49. Diagnos' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Diagnos (DGNOF), the current Equity-to-Asset is 0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnos (DGNOF) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnos stock appears to be overvalued.
The current stock price of $0.34 is trading 577.2% above its estimated GF Value™ of $0.05.
GuruFocus considers Diagnos to be Significantly Overvalued.
Key valuation signals for DGNOF:
Equity-to-Asset: 0.29
GF Value™: $0.05 vs. price of $0.34 (577.2% above fair value)
Industry Position: 40.8% below the Healthcare Providers & Services median (#510 of 687)
No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
22GF Score
Get the complete analysis for DGNOF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNOF has been successfully added to your 
